The current raucous debate over the commonly used PSA blood test to screen for prostate cancer, the third leading cause of cancer deaths in men in the U.S.(a), stems from the U.S. Preventive Services Task Forces recommendation to discontinue PSA screening(b). The debate is pitting physician against physician, cancer advocacy groups against health care insurance companies, and leaving men with enormous questions about what to do about their lifetime risk of developing prostate cancer. more... See more text